Loading...
XJPX3079
Market cap62mUSD
Jan 14, Last price  
945.00JPY
1D
0.64%
1Q
1.83%
Jan 2017
-31.07%
IPO
358.18%
Name

DVx Inc

Chart & Performance

D1W1MN
XJPX:3079 chart
P/E
57.23
P/S
0.22
EPS
16.51
Div Yield, %
3.15%
Shrs. gr., 5y
-1.08%
Rev. gr., 5y
2.57%
Revenues
45.85b
-3.44%
11,740,376,00013,080,891,00015,793,556,00018,000,829,00020,487,399,00022,872,235,00026,420,963,00028,647,863,00031,372,131,00035,266,794,00038,275,742,00040,380,089,00044,653,770,00041,007,008,00045,496,274,00047,483,757,00045,851,074,000
Net income
173m
-81.53%
236,354,000277,859,000324,845,000357,145,000476,038,000682,742,000788,549,000919,948,0001,289,737,0001,025,999,000856,128,000974,181,000792,028,000572,367,000863,016,000936,184,000172,913,000
CFO
-423m
L
349,252,000337,571,000501,606,000146,382,000457,611,0001,281,412,000283,738,000515,836,0001,311,925,0001,152,166,0001,205,839,000290,272,0001,045,392,0001,743,161,0001,687,188,0001,484,945,000-422,567,000
Dividend
Mar 28, 20250 JPY/sh

Profile

DVx Inc. engages in the import/export of medical devices and related peripheral devices in Japan. The company sells arrhythmia-related products, such as cardiac pacemakers, implantable cardioverter defibrillators, electrode catheters, and ablation catheters. It also offers ischemia-related products, including excimer laser systems; RADPAD, which reduces scatter radiation exposure to medical personnel during fluoroscopy procedures; RADNEK that reduces scatter radiation exposure to the thyroid in medical personnel during fluoroscopy procedures; RADCAP, which reduces scatter radiation exposure to the head of medical personnel during fluoroscopy procedures; and resolution/resolution SD and wonder belt products. In addition, the company engages in the research, development, manufacture, sale, repair, and leasing of medical devices and related peripheral devices; provision of internal and external medical and medical device-related general consulting and services; and medical publishing and market research activities. DVx Inc. was founded in 1986 and is headquartered in Tokyo, Japan.
URL
https://www.dvx.jp/
IPO date
Apr 25, 2007
Employees
319
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
45,851,074
-3.44%
47,483,757
4.37%
45,496,274
10.95%
Cost of revenue
41,116,505
42,042,693
40,167,523
Unusual Expense (Income)
NOPBT
4,734,569
5,441,064
5,328,751
NOPBT Margin
10.33%
11.46%
11.71%
Operating Taxes
202,599
414,386
395,806
Tax Rate
4.28%
7.62%
7.43%
NOPAT
4,531,970
5,026,678
4,932,945
Net income
172,913
-81.53%
936,184
8.48%
863,016
50.78%
Dividends
(312,135)
(258,478)
(250,017)
Dividend yield
2.96%
2.48%
2.33%
Proceeds from repurchase of equity
1,678
15,131
16,360
BB yield
-0.02%
-0.14%
-0.15%
Debt
Debt current
2,064
1,440
(35,094)
Long-term debt
22,982
18,986
Deferred revenue
(48)
Other long-term liabilities
511,480
498,697
482,802
Net debt
(7,559,723)
(9,144,797)
(8,124,474)
Cash flow
Cash from operating activities
(422,567)
1,484,945
1,687,188
CAPEX
(290,000)
(251,195)
(114,304)
Cash from investing activities
(396,557)
(477,057)
(97,487)
Cash from financing activities
(312,310)
(244,917)
(235,334)
FCF
3,702,821
5,120,846
5,467,544
Balance
Cash
7,489,404
8,614,223
7,846,380
Long term investments
95,365
551,000
243,000
Excess cash
5,292,215
6,791,035
5,814,566
Stockholders' equity
9,242,032
9,399,872
8,726,629
Invested Capital
4,430,521
2,775,753
2,788,523
ROIC
125.78%
180.68%
160.93%
ROCE
48.70%
56.87%
61.94%
EV
Common stock shares outstanding
10,429
10,397
10,356
Price
1,012.00
0.80%
1,004.00
-3.09%
1,036.00
-2.72%
Market cap
10,554,616
1.11%
10,438,758
-2.70%
10,728,952
-2.32%
EV
2,994,893
1,293,961
2,604,478
EBITDA
5,166,789
5,832,336
5,694,788
EV/EBITDA
0.58
0.22
0.46
Interest
251
125
80
Interest/NOPBT
0.01%
0.00%
0.00%